Alcon Inc (STU:2U3)
€ 54.41 0 (0%) Market Cap: 40.55 Bil Enterprise Value: 44.04 Bil PE Ratio: 39.39 PB Ratio: 2.03 GF Score: 79/100

Alcon AG at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 04:15PM GMT
Release Date Price: €54.41
David James Adlington
JPMorgan Chase & Co, Research Division - Head of Medical Technology and Services Equity Research

Good afternoon, and good morning, everybody. It's David Adlington again from JPMorgan in London. My pleasure now to introduce David Endicott, CEO of Alcon. David is going to make a presentation, and then we'll break out for Q&A. If you would like to submit a question, there's a button on your screen to do so. But with that, David, thanks for joining us today, and over to you.

David J. Endicott
Alcon Inc. - CEO & Director

Thanks, David. Look, we're excited to be here, even if it's virtual. We always like to be in San Francisco, but this will have to do for now. It seems to be the way of the world.

We're going to talk a little bit today, just a little bit about our innovation agenda for this year. We'll talk a little bit about our longer-term piece. And of course, we'll give guidance with our year-end results next month.

So let me start on Slide 3 in your deck. When we spun out in 2019, our thesis was in essence

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot